OpenEvidence users benefit from multimedia and full-text content sourced from JAMA, JAMA Network Open, and JAMA specialty journals
CAMBRIDGE, MA, June 5, 2025 – OpenEvidence, the fastest-growing platform for doctors in history, has signed a multi-year content agreement with the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications published by the American Medical Association.
Under this agreement, all published content from JAMA, JAMA Network Open, and the 11 JAMA specialty journals — JAMA Cardiology, JAMA Dermatology, JAMA Health Forum, JAMA Internal Medicine, JAMA Neurology, JAMA Oncology, JAMA Ophthalmology, JAMA Otolaryngology–Head & Neck Surgery, JAMA Pediatrics, JAMA Psychiatry, and JAMA Surgery — including full text and multimedia, will inform answers delivered on the OpenEvidence platform.
“Clinicians seek reliable information to guide their care of patients and want the best scientific evidence readily accessible, said Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor-in-Chief of JAMA and the JAMA Network. “OpenEvidence has rapidly established itself as a favored resource among clinicians, and I am pleased for the JAMA Network to join OpenEvidence as a content partner, making the peer-reviewed science from across our 13 journals more accessible to practicing clinicians.”
“The JAMA Network is well known as a trusted source of the highest-quality scientific evidence that can inform clinical decisions,” said Daniel Nadler, Founder and CEO of OpenEvidence. “Now, through this partnership, the clinical trials, observational studies, guidelines, and clinical reviews from nearly every major specialty and sub-specialty that the JAMA Network covers will be delivered in a way that clinicians need: immediately and in the palm of their hand.”
Robert M. Wachter, MD, Chair of the Department of Medicine at UCSF and author of the upcoming book, A Giant Leap: How AI is Transforming Healthcare and What That Means for Our Future, said, “Thus far, the digital transformation of healthcare has mostly fallen short in its efforts to deliver trusted, evidence-based clinical decision support to clinicians when they need it most. The partnership between JAMA, a cornerstone of medical research and analysis for more than a century, and OpenEvidence, my preferred platform for AI-powered clinical insights, represents a significant step toward fulfilling that promise. I’m confident that both clinicians and patients will benefit.”
About OpenEvidence
OpenEvidence is the fastest-growing clinical decision support platform in the United States, and the most widely used medical search engine among U.S. clinicians. Trusted by hundreds of thousands of verified physicians, nurses, and other healthcare professionals, OpenEvidence is actively used across more than 10,000 hospitals and medical centers nationwide and by over a third of doctors in the United States, to make high-stakes clinical decisions at the point of care.
Each month, over 50,000 verified U.S. clinicians register for OpenEvidence. Aside from the iPhone, there has never been a piece of technology adopted by clinicians as quickly as OpenEvidence. OpenEvidence is transforming how frontline healthcare providers access, evaluate, and apply the world’s medical knowledge.
Founded with the mission to organize and expand global medical knowledge, OpenEvidence continues to redefine evidence-based medicine in real-time. In recognition of this impact, in 2025, OpenEvidence Founder Daniel Nadler, PhD, was named to the TIME100 Health list of the 100 Most Influential People in global health.
About the JAMA Network®
The JAMA Network brings JAMA together with JAMA Network Open and 11 specialty journals to offer enhanced access to the educational content, scientific research, and opinion shaping the future of medicine. Published continuously since 1883, JAMA is one of the most widely circulated, peer-reviewed, general medical journals in the world. www.jamanetwork.com
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5252) or email media relations.